1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer (Version 4.2023). © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed [March 30, 2023]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content use or application, and disclaims any responsibility for their application or use in any way.
2. Mahtani R, Niyazov A, Lewis K, et al. Real-world study of regional differences in patient demographics, clinical characteristics, and BRCA1/2 mutation testing in patients with human epidermal growth factor receptor 2-negative advanced breast cancer in the United States, Europe, and Israel. Adv Ther. 2023;40(1):331–48.
3. Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National estimates of genetic testing in women with a history of breast or ovarian cancer. J Clin Oncol. 2017;35(34):3800–6.
4. Metastatic Breast Cancer Alliance. Genetic and biomarker testing. https://www.mbcalliance.org/projects/here-all-year/genetic-and-biomarker-testing/. Published 2022. Accessed 3 Mar 2023.
5. National Cancer Institute. Tumor Markers. https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-fact-sheet. Published 2021. Accessed 6 Mar 2023.